Biovica International – Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress
UPPSALA, Sweden, April 17, 2018 /PRNewswire/ —
New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.
The study, presented…
View more at https://www.prnewswire.com/news-releases/biovica-international—positive-results-with-divitum-from-new-pfizer-study-presented-at-the-aacr-congress-300631000.html
Comments Off on Biovica International – Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress